Avery K. Huber

Avery K. Huber

Auto-generated profile, based on publicly available information

Avery K. Huber

Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ZYZhiyuan Yao
Zhiyuan Yao
MMMcGuire Metts
McGuire Metts
AHAvery K. Huber
Avery K. Huber
JLJingjing Li
Jingjing Li
TKTomoaki Kinjo
Tomoaki Kinjo
BKBrian Kuhlman
Brian Kuhlman
Recent advances in machine learning (ML)-based protein design methods have enabled the rapid in silico generation of large libraries of miniprotein binders with minimal manual input. While computational design capacity has scaled rapidly, experimental validation methods have lagged, creating a bottleneck in binder discovery pipelines. Here, we apply mRNA display to screen an ML-designed miniprotein binder library and directly compare its performance with the more widely used yeast surface display platform using a single shared DNA library. We screened 2,009 designs targeting the platelet receptor TLT-1 and 3,159 designs targeting the immune receptor B7-H3 across both platforms. While both selection methods reliably identified functional binders, we found that mRNA display preferentially enriched binders with slower dissociation rates. In addition, mRNA display achieved higher library coverage than yeast display, likely rescuing functional designs that are penalized in a cell-based expression system. Biophysical characterization of selected binders from both platforms revealed strong binding affinities and high thermal stabilities. These results showcase the power of integrating ML-based computational design tools with rapid in vitro selection technologies, providing a scalable framework for therapeutic miniprotein discovery. IMPORTANCE: Miniprotein binders offer major advantages as next-generation therapeutics, including small size, high stability, and efficient production. In this work, we conduct a side-by-side comparison of mRNA and yeast display as platforms for high-throughput evaluation of de novo miniprotein binders. The binders generated here serve as starting points for therapeutics targeting TLT-1 or B7-H3, two clinically relevant molecules.

3 February 2022 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
LBLalitha Belur
Lalitha Belur
AHAvery Huber
Avery Huber
HMHillary Mantone
Hillary Mantone
MRMason Robertson
Mason Robertson
MSMiles Smith
Miles Smith
RMR. Scott McIvor
R. Scott McIvor